{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:56:12Z","timestamp":1793318172135,"version":"4.5.0"},"reference-count":42,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sanofi-Regeneron PATHWAYS in Type-2 Inflammation Global Innovation Grant","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2023,12,12]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It is unclear if type-2 inflammation is associated with accelerated lung function decline in individuals with asthma and chronic obstructive pulmonary disease (COPD). We tested the hypothesis that type-2 inflammation indicated by elevated blood eosinophils (BE) and fraction of exhaled nitric oxide (FeNO) is associated with accelerated lung function decline in the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included adults from the Copenhagen General Population Study with measurements of BE (N=15 605) and FeNO (N=2583) from a follow-up examination and assessed forced expiratory volume in 1\u2009s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) decline in the preceding 10 years. Based on pre- and post-bronchodilator lung function, smoking history and asthma at follow-up examination, participants were assigned as not having airway disease, asthma with full reversibility (AR), asthma with persistent obstruction (APO), COPD, and not classifiable airflow limitation (NAL).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      FEV\n                      <jats:sub>1<\/jats:sub>\n                      decline in mL\/year increased with 1.0 (95% CI 0.6 to 1.4, p&lt;0.0001) per 100\u2009cells\/\u00b5L higher BE and with 3.2 (95% CI 2.0 to 4.5, p&lt;0.0001) per 10 ppb higher FeNO. Adjusted FEV\n                      <jats:sub>1<\/jats:sub>\n                      decline in mL\/year was 18 (95% CI 17 to 20) in those with BE&lt;300\u2009cells\/\u00b5L and FeNO&lt;20\u2009ppb, 22 (19\u201325) in BE\u2265300\u2009cells\/\u00b5L or FeNO\u226520\u2009ppb, and 27 (21\u201333) in those with BE\u2265300\u2009cells\/\u00b5L and FeNO\u226520\u2009ppb (p for trend&lt;0.0001). Corresponding FEV\n                      <jats:sub>1<\/jats:sub>\n                      declines were 24 (19\u201329), 33 (25\u201340) and 44 (31\u201356) in AR (0.002), 26 (14\u201337), 36 (12\u201360) and 56 (24\u201389) in APO (0.07), 32 (27\u201336), 31 (24\u201338) and 44 (24\u201365) in COPD (0.46), and 27 (21\u201333), 35 (26\u201345), and 37 (25\u201349) in NAL (0.10), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Type-2 inflammation indicated by elevated BE and FeNO is associated with accelerated FEV\n                      <jats:sub>1<\/jats:sub>\n                      decline in individuals with chronic airway disease in the general population, and this association was most pronounced in an asthma-like phenotype.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2023-220972","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T01:14:23Z","timestamp":1704849263000},"page":"349-358","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":82,"title":["Type-2 inflammation and lung function decline in chronic airway disease in the general population"],"prefix":"10.1136","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-829X","authenticated-orcid":false,"given":"Yunus","family":"\u00c7olak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1442-4694","authenticated-orcid":false,"given":"Shoaib","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-4190","authenticated-orcid":false,"given":"Jacob Louis","family":"Marott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Vestbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge Gr\u00f8nne","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0401-0081","authenticated-orcid":false,"given":"Peter","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"2025042101250971000_79.4.349.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00157-9"},{"key":"2025042101250971000_79.4.349.2","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"key":"2025042101250971000_79.4.349.3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cea.12881","article-title":"The current and future role of biomarkers in type 2 cytokine-mediated asthma management","volume":"47","author":"Pavord","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"2025042101250971000_79.4.349.4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01457-2017","article-title":"Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD","volume":"51","author":"Alc\u00e1zar-Navarrete","year":"2018","journal-title":"Eur Respir J"},{"key":"2025042101250971000_79.4.349.5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03823-2020","article-title":"Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung health study","volume":"58","author":"Park","year":"2021","journal-title":"Eur Respir J"},{"key":"2025042101250971000_79.4.349.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201104-0597OC"},{"key":"2025042101250971000_79.4.349.7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04590-2020","article-title":"Blood eosinophil counts in the general population and Airways disease: a comprehensive review and meta-analysis","volume":"59","author":"Benson","year":"2022","journal-title":"Eur Respir J"},{"key":"2025042101250971000_79.4.349.8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/cea.12935","article-title":"High fractional exhaled nitric oxide and Sputum Eosinophils are associated with an increased risk of future virus-induced exacerbations: A prospective cohort study","volume":"47","author":"Bjerregaard","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"2025042101250971000_79.4.349.9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00616-2018","article-title":"Combined value of exhaled nitric oxide and blood Eosinophils in chronic airway disease: the Copenhagen general population study","volume":"52","author":"\u00c7olak","year":"2018","journal-title":"Eur Respir J"},{"key":"2025042101250971000_79.4.349.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.06.007"},{"key":"2025042101250971000_79.4.349.11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jaci.2016.01.044","article-title":"Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity","volume":"138","author":"Malinovschi","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2025042101250971000_79.4.349.12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2025042101250971000_79.4.349.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201509-1869OC"},{"key":"2025042101250971000_79.4.349.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"2025042101250971000_79.4.349.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"2025042101250971000_79.4.349.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303951"},{"key":"2025042101250971000_79.4.349.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"2025042101250971000_79.4.349.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708208"},{"key":"2025042101250971000_79.4.349.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200402-230OC"},{"key":"2025042101250971000_79.4.349.20","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2213-2600(16)00098-9","article-title":"Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen city heart study: a prospective population-based analysis","volume":"4","author":"Lange","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025042101250971000_79.4.349.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810223391703"},{"key":"2025042101250971000_79.4.349.22","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04656-2020","article-title":"The coexistence of asthma and COPD: risk factors, clinical history and lung function Trajectories","volume":"58","author":"Marcon","year":"2021","journal-title":"Eur Respir J"},{"key":"2025042101250971000_79.4.349.23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.anai.2022.06.028","article-title":"Plasma immunoglobulin E and risk of exacerbation and mortality in chronic obstructive pulmonary disease: A contemporary population-based cohort","volume":"129","author":"\u00c7olak","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025042101250971000_79.4.349.24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1164\/rccm.202110-2441OC","article-title":"Prognosis of patients with chronic obstructive pulmonary disease not eligible for major clinical trials","volume":"206","author":"\u00c7olak","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025042101250971000_79.4.349.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200406-710ST"},{"key":"2025042101250971000_79.4.349.26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00165106"},{"key":"2025042101250971000_79.4.349.27","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.10.847"},{"key":"2025042101250971000_79.4.349.28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1164\/rccm.201605-1014OC","article-title":"Acute exacerbations and lung function loss in Smokers with and without chronic obstructive pulmonary disease","volume":"195","author":"Dransfield","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2025042101250971000_79.4.349.29","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2021-217032"},{"key":"2025042101250971000_79.4.349.30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1164\/rccm.202104-1040LE","article-title":"Fractional exhaled nitric oxide Nonsuppression identifies corticosteroid-resistant type 2 signaling in severe asthma","volume":"204","author":"Couillard","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025042101250971000_79.4.349.31","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00838-2020","article-title":"High eosinophil counts predict decline in FEV1: results from the Cancold study","volume":"57","author":"Tan","year":"2021","journal-title":"Eur Respir J"},{"key":"2025042101250971000_79.4.349.32","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02536-2017","article-title":"Associations between blood Eosinophils and decline in lung function among adults with and without asthma","volume":"51","author":"Hancox","year":"2018","journal-title":"Eur Respir J"},{"key":"2025042101250971000_79.4.349.33","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01785-2017","article-title":"Predictors of accelerated decline in lung function in adult-onset asthma","volume":"51","author":"Coumou","year":"2018","journal-title":"Eur Respir J"},{"key":"2025042101250971000_79.4.349.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202005-1854OC"},{"key":"2025042101250971000_79.4.349.35","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0185-2020","article-title":"Does the use of inhaled corticosteroids in asthma benefit lung function in the long-term? A systematic review and meta-analysis","volume":"30","author":"Tan","year":"2021","journal-title":"Eur Respir Rev"},{"key":"#cr-split#-2025042101250971000_79.4.349.36.1","doi-asserted-by":"crossref","unstructured":"Pavord ID , Brusselle G , Jackson DJ . Feno as a potential Prognostic and predictive marker of lung function decline in patients with uncontrolled, moderate-to-severe ASTHMA: LIBERTY ASTHMA QUEST. American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A3418"},{"key":"#cr-split#-2025042101250971000_79.4.349.36.2","doi-asserted-by":"crossref","unstructured":"May 2022 doi:10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A3418","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A3418"},{"key":"2025042101250971000_79.4.349.37","first-page":"974","article-title":"Longitudinal changes in forced Expiratory volume in one second in adults. Methodologic considerations and findings in healthy Nonsmokers","volume":"133","author":"Burrows","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"2025042101250971000_79.4.349.38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01359-2015"},{"key":"2025042101250971000_79.4.349.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30879-6"},{"key":"2025042101250971000_79.4.349.40","doi-asserted-by":"crossref","first-page":"106852","DOI":"10.1016\/j.rmed.2022.106852","article-title":"Potential clinical implications of targeted Spirometry for detection of COPD: A contemporary population-based cohort study","volume":"197","author":"\u00c7olak","year":"2022","journal-title":"Respir Med"},{"key":"2025042101250971000_79.4.349.41","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1411532","article-title":"Lung-function Trajectories and chronic obstructive pulmonary disease","volume":"373","author":"Lange","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2023-220972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T07:00:12Z","timestamp":1745218812000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2023-220972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,15]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/thorax-2023-220972"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2023-220972","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]}}}